Mivacurium

Class Non-depolarising NMJ blocker
Chemistry

Benzylisoquinolinium diester

Routes of administration

IV only

Absorption

Poor absorption; minimal oral bioavailability

Solubility

pKa=18.59; good water solubility

Distribution

VOD= 0.15-0.34L/kg, 28% protein bound

Metabolism

Metabolised by butyrylcholinesterase

Elimination

Minimal renal or hepatic clearance

Time course of action

Half lives of most isomers are short (2-5 minutes)

Target receptor

Nicotinic acetylcholine receptors at the neuromuscular junction

Mechanism of action

Nondepolarising neuromuscular junction blocker (competitive antagonist of acetylcholine); by binding to the nicotinic acetylcholine receptor, this agent blocks the binding of acetylcholine, and prevents the cation channel from opening, thus preventing the depolarisation of the motor endplate.

Clinical effects

Nondepolarising neuromuscular junction blockade;
No autonomic effects (i.e no ganglionic blockade or vagolytic effects)
However, does cause hypotension via systemic histamine release

Literature reference

Rubin et al (1995)

CICM details of understanding Not specifically listed in the CICM syllabus
Mentioned around Deranged Physiology
Related SAQs